Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-484 mimic
- Development stage
- Preclinical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intratumoral, Intravenous
01
Overview
miR-484 mimic is a synthetic, double-stranded RNA oligonucleotide designed to mimic the activity of endogenous microRNA-484 (miR-484). It is primarily utilized as a research-use-only laboratory tool to investigate the functional roles of miR-484 in various biological processes and diseases, particularly in oncology and ischemic injuries. miR-484 acts as a post-transcriptional regulator by binding to the 3'-untranslated region (3'-UTR) of target mRNAs, leading to translational repression or mRNA degradation. Key validated targets of miR-484 include HOXA5, BCL2L13, YAP1, PECAM1, PSMG1, CDA, VEGFB, and VEGFR2. Depending on the cellular context and cancer type, miR-484 can act as either an oncogene (e.g., in triple-negative breast cancer, cervical cancer, and prostate cancer) or a tumor suppressor (e.g., in gastric cancer and ovarian cancer).
- Other names
- hsa-miR-484 agomirhsa-miR484 agomirhsa-miR 484 agomirhsa-miR-484 mimichsa-miR484 mimichsa-miR 484 mimicmiR-484 agomirmiR484 agomirmiR 484 agomirmicroRNA-484 mimicmicroRNA484 mimicmicroRNA 484 mimic
02
Targets
BCL2L13HOX (HOX transcription factor family)VEGFR2 (Vascular endothelial growth factor receptor 2)DUSP2 (Proteasome assembly chaperone 1)VEGFB (Vascular endothelial growth factor B)TEAD (TEAD family)CDA (Cytidine deaminase)PECAM1 (PECAM-1)
Beyond the preview
Go deeper on miR-484 mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-484 mimic.